Essex Investment Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Essex Investment Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-16,485	Closed	-$1.13M	–	485
2021 Q1	$1.13M	Buy	+16,485	New	+$1.33M	0.14%	223
2020 Q4	–	Sell	-33,130	Closed	-$2.15M	–	529
2020 Q3	$2.15M	Sell	33,130 -13,199	-28%	-$865K	0.31%	107
2020 Q2	$3.39M	Sell	46,329 -21,934	-32%	-$1.17M	0.56%	44
2020 Q1	$2.32M	Buy	68,263 +16,507	+32%	+$755K	0.47%	57
2019 Q4	$2.82M	Buy	51,756 +14,830	+40%	+$734K	0.35%	83
2019 Q3	$1.54M	Sell	36,926 -7,760	-17%	-$328K	0.22%	147
2019 Q2	$1.96M	Buy	44,686 +17,965	+67%	+$1.01M	0.27%	125
2019 Q1	$1.38M	Buy	+26,721	New	+$1.15M	0.2%	162

Other funds holding BHVN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Essex Investment Management's BHVN Position: Q2 2021 in Review

Essex Investment Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2021, closing a stake of 16,485 shares — an estimated $1.13M sold.

Essex Investment Management first reported a position in BHVN in Q1 2019 and held it in 8 quarters. The position peaked at $3.39M in Q2 2020. 223 funds tracked by Wall St. Rank hold BHVN as of Q2 2021.

Essex Investment Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2021 after selling out during the quarter.
Essex Investment Management sold 16,485 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2021, an estimated $1.13M.
Essex Investment Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 8 quarters.
Essex Investment Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $3.39M in Q2 2020.
223 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2021.

Based on Essex Investment Management's 13F filing for Q2 2021, filed 12 Aug 2021.